Strategies for Improving Adherence to Oral Oncolytics

At the National Community Oncology Dispensing Association's (NCODA) 2018 Spring Summit, Julianne Orr, PharmD, from Indiana University Health Simon Cancer Center, discusses the pharmacist's role in managing adherence to oral treatment regimens for patients with cancer.


Transcript: "At IU Health, we speak to patients at initial education, so before they start the medication, and then we follow up with every cycle. So depending on the oral agent they're on, that may be 3 weeks or it may be 6 weeks, it depends on the patient. And our role in that is making sure we're assessing adherence, so answering any questions that they may have, reiterating how they should take the drug (with or without food), and then assessing obviously any medication changes, interactions, and adverse events. We do that on a cycle basis right now, so that is a pharmacist speaking to those patients."

Most Popular

Related Articles

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.
Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$